{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T23:32:10Z","timestamp":1777851130160,"version":"3.51.4"},"reference-count":34,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Geriatr Psychiatry Neurol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Istradefylline, a selective adenosine A2A receptor antagonist, is used as an adjunct therapy to levodopa to improve motor symptoms in Parkinson\u2019s disease (PD) patients, particularly those experiencing wearing-off phenomena. This study integrates safety data on istradefylline for the treatment of PD from randomized controlled trials (RCTs) and the FDA Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a systematic search of PubMed, EMBASE, Ovid, MEDLINE, and ClinicalTrials.gov for RCTs on istradefylline safety in PD patients up to September 2024. A random-effects meta-analysis estimated the Peto odds ratio (OR) with 95% confidence intervals (CIs). FAERS data were analyzed through disproportionality measures, including the proportional reporting ratio (PRR) and reporting odds ratio (ROR), with signal refinement to primary suspect cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The safety meta-analysis, encompassing data from 8 RCTs, reveals a significant association between istradefylline treatment and an increased risk of dyskinesia (odds ratio [OR] 1.77, 95% CI 1.32-2.36;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01), hallucinations (OR 2.08, 95% CI 1.11-3.90;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02), and nausea, when compared with placebo. In the FAERS database, 2597 patients were identified with adverse events (AEs) linked to istradefylline. Disproportionality analysis of istradefylline revealed 39 AEs strongly associated with its use, all of which were substantiated through signal refinement. The most commonly reported AEs were primarily associated with nervous system and psychiatric disorders.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights distinct AE patterns for istradefylline in trials vs real-world data, underscoring the importance of post-marketing surveillance to detect underreported AEs and validate new safety signals effectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08919887251343608","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T10:33:34Z","timestamp":1747823614000},"page":"3-13","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety Profile of Istradefylline in Parkinson\u2019s Disease: A Meta-Analysis of Randomized Controlled Trials and Disproportionality Analysis Using FAERS"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3584-6212","authenticated-orcid":false,"given":"Beema T","family":"Yoosuf","sequence":"first","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research (NIPER)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhani","family":"Jain","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research (NIPER)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-6839","authenticated-orcid":false,"given":"Muhammed Favas","family":"KT","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research (NIPER)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4520-3293","authenticated-orcid":false,"given":"Dipika","family":"Bansal","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research (NIPER)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18339-1"},{"key":"e_1_3_6_3_2","first-page":"14","article-title":"Symptomatology and clinical features of Parkinson\u2019s disease. Experimental and clinical evidence of the neuropathology of Parkinson\u2019s disease","volume":"1","author":"El Khiat A","year":"2023","unstructured":"El Khiat A, El-Mansoury B, Ali DA, et al. Symptomatology and clinical features of Parkinson\u2019s disease. Experimental and clinical evidence of the neuropathology of Parkinson\u2019s disease. IGI Global. 2023;1:14-24.","journal-title":"IGI Global"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/biology9050103"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.4103\/aian.aian_647_21"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137183"},{"issue":"5","key":"e_1_3_6_7_2","first-page":"441","article-title":"Current pharmacological treatment for Parkinson's disease","volume":"75","author":"Saitoh Y","year":"2023","unstructured":"Saitoh Y, Takahashi K. Current pharmacological treatment for Parkinson's disease. Brain and nerve= Shinkei kenkyu no shinpo. 2023;75(5):441-449.","journal-title":"Brain and nerve= Shinkei kenkyu no shinpo"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-58460-6"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01429-0"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.2174\/0118715273258646230920074421"},{"key":"e_1_3_6_11_2","unstructured":"FDA approves new add-on drug to treat off episodes in adults with Parkinson\u2019s disease 2019. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-add-drug-treat-episodes-adults-parkinsons-disease"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2022.01.032"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2023.100224"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2201374"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00574-6"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2010.02.007"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1201\/9781032629940-6"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1201\/9781032629940-9"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000313834.22171.17"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2011.09.023"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000081227.84197.0B"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22095"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21315"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25418"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23107"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2009.06.008"},{"key":"e_1_3_6_28_2","first-page":"97","article-title":"Istradefylline for off episodes in Parkinson's disease: a us perspective of common clinical scenarios","volume":"12","author":"Isaacson SH","year":"2022","unstructured":"Isaacson SH, Bett\u00e9 S, Pahwa R. Istradefylline for off episodes in Parkinson's disease: a us perspective of common clinical scenarios. Degener Neurol Neuromuscul Dis. 2022;12:97-109.","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint12030017"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.5692\/clinicalneurol.cn-001740"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2018.11.005"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2022.136515"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05676-1"},{"key":"e_1_3_6_34_2","first-page":"1","article-title":"Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms","author":"Yoosuf BT","year":"2024","unstructured":"Yoosuf BT, Favas Kt M, Dutta P, Bansal D. Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms. Expet Opin Drug Saf. 2024;1-13.","journal-title":"Expet Opin Drug Saf"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-83014-1"}],"container-title":["Journal of Geriatric Psychiatry and Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08919887251343608","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08919887251343608","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08919887251343608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:17:07Z","timestamp":1777501027000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08919887251343608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/08919887251343608"],"URL":"https:\/\/doi.org\/10.1177\/08919887251343608","relation":{},"ISSN":["0891-9887","1552-5708"],"issn-type":[{"value":"0891-9887","type":"print"},{"value":"1552-5708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]}}}